Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Recombination low-dosage human alpha-2b(IFN-alpha-2b) interferon lozenge and preparing method thereof

An interferon, low-dose technology, applied in the field of medical and bioengineering, can solve the problems of small number of subtypes and unsatisfactory disease curative effect, and achieve the effect of obvious curative effect.

Inactive Publication Date: 2004-02-04
山东泉港药业有限公司
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Australia's Namalwa cell interferon buccal tablet is a kind of lymphoblastoid interferon. This kind of interferon is made of lymphoma, which is a normal tissue of a non-healthy human body, and the number of subtypes is small, so the curative effect on the disease is not ideal , therefore, my country has not approved the import

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] A low-dose recombinant human α-2b (IFN-α-2b) interferon buccal tablet of the present invention, its formula is:

[0032] Low dose recombinant human α-2b (IFN-α-2b) interferon 100IU

[0033] Trehalose Powder 6%

[0034] Maltose powder 5%

[0035] Powdered sugar 55%

[0036] Starch 31%

[0037] Gelatin powder 2%

[0038] Magnesium Stearate 1%

Embodiment 2

[0040] A low-dose recombinant human α-2b (IFN-α-2b) interferon buccal tablet of the present invention, its formula is:

[0041] Low dose recombinant human α-2b (IFN-α-2b) interferon 300IU

[0042] Trehalose Powder 8%

[0043] Maltose Powder 6%

[0044] Powdered sugar 48%

[0045]Starch 35%

[0046] Gelatin powder 2%

[0047] Magnesium Stearate 1%

Embodiment 3

[0049] A low-dose recombinant human α-2b (IFN-α-2b) interferon buccal tablet of the present invention, its formula is:

[0050] Low dose recombinant human α-2b (IFN-α-2b) interferon 1000IU

[0051] Trehalose Powder 8%

[0052] Maltose Powder 8%

[0053] Powdered sugar 46%

[0054] Starch 35%

[0055] Gelatin powder 2%

[0056] Magnesium Stearate 1%

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A buccal lozenge for treating SARS, hepatitis B, hepatitis C and tumor is prepared from low-dosage recombinant human alpha-2b(IFN-alpha-2b) interferon and medical auxiliaries including mycose, maltose, sugar powder, staroh, gelatin and magnesium stearate. Its advantages are high curative effect, low poison, and low cost.

Description

Technical field [0001] The invention relates to the technical field of medical bioengineering, in particular to preparation of buccal tablets by using low-dose recombinant human alpha-2b (IFN-alpha-2b) interferon and a preparation method thereof. Background technique [0002] As a cytokine, interferon has a wide range of biological functions, such as anti-virus, anti-tumor, immune regulation, regulation of cell proliferation and differentiation, etc., and has been approved for clinical treatment in more than 40 countries. However, intramuscular injection or intravenous infusion is mostly used for its drug administration, and the injection dose is relatively large, generally 1 million to 6 million IU. The dosage of interferon buccal tablets is relatively low (100-10000IU). Australia's Namalwa cell interferon buccal tablet is a kind of lymphoblastoid interferon. This kind of interferon is made of lymphoma, which is a normal tissue of a non-healthy human body, and the number o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/20A61K38/21A61P31/12A61P35/00A61P37/02
Inventor 陈文芳刘红军宋磊邹立家
Owner 山东泉港药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com